1. Chen DW, Lang BH, McLeod DS, Newbold K, Haymart MR. Thyroid cancer. Lancet 2023;401:1531-1544.
3. Ahn HS, Kim HJ, Welch HG. Korea’s thyroid-cancer “epidemic”: screening and overdiagnosis. N Engl J Med 2014;371:1765-1767.
4. Park B, Kim C, Kim J. Recent advances in ultrasound and photoacoustic analysis for thyroid cancer diagnosis. Adv Phys Res 2023;2:2200070.
7. Edge SB; American Joint Committee on Cancer; American Cancer Society. AJCC cancer staging handbook: from the AJCC cancer staging manual. Springer; 2010.
8. Young JL Jr, Roffers SD, Ries LA, Fritz AG, Hurlbut AA. SEER summary staging manual: 2000 codes and coding instructions. NIH Pub. No. 01-4969, B. National Cancer Institute; 2001.
10. Shin DY, Kang H, Kim SW, et al. Korean Thyroid Association Guidelines on the Management of Differentiated Thyroid Cancers; Part III. Management of advanced differentiated thyroid cancers. Chapter 4. Systemic therapy for progressive radioiodine-refractory differentiated thyroid cancer 2024. Int J Thyroidol 2024;17:168-181.
12. Kim M, Kim WG, Park S, et al. Initial size of metastatic lesions is best prognostic factor in patients with metastatic differentiated thyroid carcinoma confined to the lung. Thyroid 2017;27:49-58.
13. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-247.
17. Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 2015;372:621-630.
19. Lee SE, Lee MS, Bang H, Kim MY, Choi YL, Oh YL. NTRK fusion in a cohort of BRAF p. V600E wild-type papillary thyroid carcinomas. Mod Pathol 2023;36:100180.
20. Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731-739.
26. Subbiah V, Hu MI, Wirth LJ, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol 2021;9:491-501.
27. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. Lancet Oncol 2020;21:271-282.
28. Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol 2018;36:7-13.
29. Brose MS, Robinson B, Sherman SI, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2021;22:1126-1138.
32. Park YJ, Lee EK, Song YS, et al. 2023 Korean Thyroid Association management guidelines for patients with thyroid nodules. Int J Thyroidol 2023;16:1-31.